Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

Live Investor Conference & Webinar: Venture Companies Present August 6th

Canada NewsWire August 3, 2020

MindMed Completes Dosing 18-MC Phase 1 Study

Canada NewsWire July 28, 2020

MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

Canada NewsWire June 26, 2020

MindMed Developing IP For Personalized Psychedelic Assisted Therapies

Canada NewsWire June 24, 2020

These are Some of The Top Companies to Watch in the Booming Psychedelics Industry

Livemoney June 18, 2020

MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

PR Newswire June 18, 2020

The Top Healthcare Bullboards: April - June 2020

Stockhouse Editorial June 17, 2020

Psychedelics Quickly Creating a Potential $100 Billion Market Opportunity

Livemoney June 12, 2020

These Companies Want to Give You LSD to Treat a Range of Mental Health Issues

Livemoney June 9, 2020

New Psychedelics Stocks and Acquisitions

Omri Wallach June 8, 2020

Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients

PR Newswire June 8, 2020

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

Canada NewsWire June 4, 2020

Psilocybin: The Weight Loss Secret We've Been Searching For?

Livemoney June 4, 2020

MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Canada NewsWire June 2, 2020

MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies

PR Newswire May 27, 2020

MindMed Closes Upsized Financing of $13.2m to Advance UHB Liechti Lab Collaboration for Next-Gen Psychedelic Inspired Medicines

Canada NewsWire May 26, 2020

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Canada NewsWire May 21, 2020

It's Time to Revisit Psychedelic Drugs That Are Proving Useful for Health

Livemoney May 21, 2020

MindMed Reports First Quarter 2020 Results and Corporate Update

Canada NewsWire May 14, 2020

Psilocybin May be the Key to Treating a Range of Health Issues, Including Obesity

Livemoney May 14, 2020